Drugs
Renal cell carcinoma (RCC) is the eighth most commonly diagnosed malignancy in the United States, with localized disease found in about 55% of patients. Standard therapy has undergone significant change, with cytokines like interferon alfa and aldesleukin largely displaced by molecularly targeted agents such as sorafenib tosylate, sunitinib malate, and
Drugs
Seattle Genetics, a clinical stage biotechnology company focused on cancer and autoimmune disease therapies, announced that its management team will present at the Fourth Annual JMP Securities Healthcare Focus Conference on October 5, 2009. The company's lead product candidate, brentuximab vedotin (SGN-35), is in a pivotal trial under
Drugs
Researchers at the University of Buenos Aires, Argentina, have identified a novel approach to targeting cancer cells by leveraging the microenvironment's increased reactive oxygen species (ROS) production. By developing a chimeric promoter that responds to ROS fluctuations, they created a gene therapy that selectively inhibits cancer cell growth
Cancer
Recent research from the University of Leicester, United Kingdom, has unveiled the cancer chemopreventive properties of cyanidin-3-glucoside (C3G), an anthocyanin component found in fruits and berries. The study, led by T.H. Marczylo, found that C3G possesses significant pharmacological activity in mouse models of carcinogenesis, with the potential to target
Cancer research
Researchers at the National Institutes of Health have successfully engineered T cells to target and kill cancer cells in patients with chronic lymphocytic leukemia (CLL). Using a technique called chimeric antigen receptor (CAR) therapy, they created T cells that recognize and destroy CLL cells. The study, published in the Journal
Cancer research
Pancreatic cancer researchers in Japan have discovered that the effectiveness of adenovirus-mediated gene therapy is impaired in radioresistant pancreatic cancer cells. The study, published in Cancer Science, compared the transduction efficiency of adenovirus-delivered genes in radiosensitive and radioresistant cells, revealing that radioresistant cells exhibited significantly lower levels of NK4, a
Cancer
Lung cancer is a leading cause of cancer death worldwide, with a high incidence of metastasis making it a formidable challenge for treatment. Novel and effective treatments are urgently needed, and researchers have been exploring cancer-specific targeted gene therapy as a potential solution. Recent data from a study conducted in
Cancer
Recent research from the Medical University of South Carolina has shed new light on the potential of TRAIL, a protein involved in immunosurveillance, as a cancer therapy. The study, published in the Journal of Urology, found that TRAIL can induce apoptosis in cancer cells, but not in normal cells. However,
Cancer research
A new report has discussed the research findings on the combined use of paclitaxel and siRNA targeting HPV16 oncogenes to improve cytotoxicity for cervical carcinoma. According to a study from Headington, the United Kingdom, the continuous expression of the E6 and E7 oncoproteins of the high-risk human papillomaviruses disrupts cellular
Cancer research
Research conducted by scientists at the University of Salamanca, Spain, has shed light on the mechanisms behind the cancer-fighting properties of resveratrol. The study, titled "Involvement of mitochondria and recruitment of Fas/CD95 signaling in lipid rafts in resveratrol-mediated antimyeloma and antileukemia actions," found that resveratrol induces apoptosis
Cancer
Scientists in Xian, People's Republic of China, have reported a novel approach to enhance radiosensitivity in breast cancer cells using a survivin promoter-driven adenoviral system expressing the PUMA gene. This gene has been identified as a potent proapoptotic molecule, and its overexpression has been shown to induce apoptosis
Cancer research
Researchers at the National Institutes of Health have made a groundbreaking discovery in the fight against melanoma, the deadliest form of skin cancer. Through the power of DNA sequencing, a team led by Yardena Samuels, Ph.D., identified a new group of genetic mutations involved in melanoma, with some mutations
